medline.ch Onkologie Urologische Tumoren

tellmed.ch

medline.ch

En | De

Impressum | Feedback

Keine Artikel ausgewählt!

Warenkorb

Sie sind hier: Onkologie » Urologische Tumoren

17. Mai 2012

Kardiovaskuläre Erkrankungen

Muskuloskelettale Erkrankungen

Gynäkologische Tumoren

Schrift:

Seite 1 von 3869


	Artikel 1 - 20 / 77368

	Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. Saylor PJ, Karoly ED, Smith MR. PMID: 22589396 [PubMed - as supplied by publisher]
	A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. PMID: 22586320 [PubMed - in process]
	A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S. PMID: 22586051 [PubMed - in process]
	Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial. J Clin Oncol. Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA. PMID: 22585689 [PubMed - as supplied by publisher]
	Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20?ng/ml in multi-core prostate biopsy? Prostate. Oh JJ, Jeong SJ, Jeong CW, Byun SS, Hong SK, Choe G, Lee SE. PMID: 22585359 [PubMed - as supplied by publisher]
	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. J Urol. Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS. PMID: 22583636 [PubMed - as supplied by publisher]
	Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy. J Urol. Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. PMID: 22583635 [PubMed - as supplied by publisher]
	Targeted therapy for advanced urothelial cancer of the bladder: Where do we stand? Anticancer Agents Med Chem. Zhu Z, Shen Z, Xu C. PMID: 22583418 [PubMed - as supplied by publisher]
	Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. Cancer Causes Control. Ros MM, Gago-Dominguez M, Aben KK, Bueno-de-Mesquita HB, Kampman E, Vermeulen SH, Kiemeney LA. PMID: 22581032 [PubMed - as supplied by publisher]
	Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radiol Med. Rinaldi D, Fiocchi F, Ligabue G, Bianchi G, Torricelli P. PMID: 22580813 [PubMed - as supplied by publisher]
	Target registration errors with surface imaging system in conformal radiotherapy for prostate cancer: study on 19 patients. Radiol Med. Bartoncini S, Fiandra C, Ruo Redda MG, Allis S, Munoz F, Ricardi U. PMID: 22580804 [PubMed - as supplied by publisher]
	The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma. J Mol Diagn. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. PMID: 22580180 [PubMed - as supplied by publisher]
	Re: denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. J Urol. PMID: 22579177 [PubMed - in process]
	Re: surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. J Urol. PMID: 22579176 [PubMed - in process]
	Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Urol. PMID: 22579172 [PubMed - in process]
	Re: electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. J Urol. PMID: 22579171 [PubMed - in process]
	Re: Accuracy of Multi-Detector Computed Tomography (MDCT) in Staging of Renal Cell Carcinoma (RCC): Analysis of Risk Factors for Mis-Staging and its Impact on Surgical Intervention. J Urol. PMID: 22579168 [PubMed - in process]
	Prospective Randomized Multicenter Study Comparing Prostate Cancer Detection Rates of End-fire and Side-fire Transrectal Ultrasound Probe Configuration. Urology. Rom M, Pycha A, Wiunig C, Reissigl A, Waldert M, Klatte T, Remzi M, Seitz C. PMID: 22578920 [PubMed - as supplied by publisher]
	Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. J Urol. Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical, Translational Research Group (EMPaCT). PMID: 22578727 [PubMed - as supplied by publisher]
	Automated vs. Manual Pattern Recognition of 3D (1)H MRSI Data of Patients with Prostate Cancer. Acad Radiol. Zechmann CM, Menze BH, Kelm BM, Zamecnik P, Ikinger U, Giesel FL, Thieke C, Delorme S, Hamprecht FA, Bachert P. PMID: 22578226 [PubMed - in process]

Artikel 1 - 20 / 77368

Seite 1 von 3869

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch Tel: +41 (0)44 204 16 77 Fax: +41(0)44 204 16 70
	Disclaimer \| Privacy Policy